Ferroportin inhibitors

VIT-2763

 Update: 01 February 2019

A randomized, controlled, multi-centred phase 2 proof-of-concept trial will begin in the second half of 2019 to assess the effectiveness of the oral ferroportin inhibitor (VIT-2763) on iron overload in β-thalassaemia patients.

Phase 1 trials have shown positive results with a consistent lower serum iron for up to 24 hours post-dose. The results are dose-dependent.

Treatment with VIT-2763 can improve iron metabolism and the production of RBCs.

Sources:

http://www.viforpharma.com/~/media/Files/V/Vifor-Pharma/documents/en/media-releases/2019/pr-vifor-pharma-ferroportin-inhibitor-en.pdf